Senhwa Biosciences Receives NT$500 Million Commitment from GEM for AI-Driven Drug Development

Apr 14, 2026
Senhwa Biosciences has signed an MOU with GEM Yield Bahamas for up to NT$500 million in funding to support its AI-enabled drug discovery and global expansion.

Taipei-based Senhwa Biosciences has signed a Memorandum of Understanding with GEM Yield Bahamas, an affiliate of Global Emerging Markets, to secure up to NT$500 million in strategic funding announced in a press release. The investment will support Senhwa’s AI-enabled drug discovery programs, clinical pipeline, and international expansion.

Senhwa has been developing an AI-driven platform for oncology research, including collaborations with Y Combinator-backed company CellType. The company uses CellType’s C2S (cell-to-sentence) technology to analyze tumor microenvironments and identify potential combination therapies. AI validation has shown promising immunomodulatory effects for Senhwa’s lead candidates.

The funding from GEM is expected to accelerate Senhwa’s research in cancer immunotherapy and advance its “cold-to-hot tumor” strategy. GEM, headquartered in Luxembourg, has completed more than 590 transactions across 75 countries through its global investment vehicles.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.